Guardant Health Earnings & Forecasts

Guardant Health (GH) earnings history, EPS estimates, revenue forecasts and company guidance.

Earnings Per Share (Non-GAAP)

분기별 실적 서프라이즈 금액

회계 분기	보고된 날짜	실제 EPS	예상 EPS	놀라다 %
Q2	Jul 30, 2026	$-0.42	$-0.46	8.70 %
Q1	May 7, 2026	$-0.45	$-0.52	13.5 %
Q4	Feb 19, 2026	$-0.50	$-0.61	18.0 %
Q3	Oct 29, 2025	$-0.39	$-0.61	36.1 %

Quarterly Revenue (Billions)

분기별 수익 깜짝 금액

회계 분기	보고된 날짜	실제 수익	예상 수익	놀라다 %
Q2	Jul 30, 2026	$334.98M	$314.90M	6.38 %
Q1	May 7, 2026	$301.67M	$278.95M	8.14 %
Q4	Feb 19, 2026	$281.27M	$275.35M	2.15 %
Q3	Oct 29, 2025	$265.20M	$235.25M	12.7 %

Guardant Health Guidance

Guardant Health (GH)는 7월 30, 2026에 fiscal year 2026에 대한 가이던스를 마지막으로 발표했습니다. 회사는 해당 기간의 매출을 $1.34B - $1.36B 범위로 예상했습니다.

이전 가이던스와 비교하여 Guardant Health는 매출 전망치를 이전 범위인 상향 조정됨에서 $1.3B - $1.32B로 상향 조정했습니다.

Guardant Health은 24과 11월 3, 2022 사이에 7월 30, 2026개의 지침 업데이트를 발표했습니다. During this period, the company raised its outlook 18 times and lowered it 4 times, providing investors with insight into management's evolving expectations.

Recent Earnings Results

Metric	Q2 '26	Q1 '26	Q4 '25	Q3 '25
Earnings Per Share (Non-GAAP)
Estimate	$-0.46	$-0.52	$-0.61	$-0.61
Actual	$-0.42	$-0.45	$-0.50	$-0.39
Surprise	+8.70%	+13.5%	+18.0%	+36.1%
Revenue
Estimate	$314.9M	$278.9M	$275.4M	$235.2M
Actual	$335.0M	$301.7M	$281.3M	$265.2M
Surprise	+6.38%	+8.14%	+2.15%	+12.7%

Analyst Estimates — Forward PeriodsSource: Wall Street consensus

Metric	Q3 '26E	Q4 '26E	Q1 '27E	Q2 '27E
Earnings Per Share (Non-GAAP)
Consensus	$-0.37	$-0.36	$-0.69	$-0.58
Revenue
Consensus	$349.6M	$367.2M	—	—

More with Benzinga EdgeGet Access

Earnings & Guidance News

PRO
Guardant Health Raises FY2026 Sales Guidance from $1.300B-$1.320B to $1.340B-$1.360B vs $1.314B Est

Guardant Health (NASDAQ:GH) raises FY2026 sales outlook from $1.300 billion-$1.320 billion to $1.340 billion-$1.360 billion vs $1.314 billion estimate.

Benzinga Newsdesk

PRO
Guardant Health Q2 Adj. EPS $(0.42) Misses $(0.41) Estimate, Sales $334.978M Beat $314.226M Estimate

Guardant Health (NASDAQ:GH) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $(0.41) by 2.44 percent. This is a 4.55 percent increase over losses of $(0.44) per share from

Benzinga Newsdesk

PRO
Guardant Health Raises FY2026 Sales Guidance from $1.250B-$1.280B to $1.300B-$1.320B vs $1.271B Est

2026 GuidanceGuardant Health now expects full year 2026 revenue to be in the range of $1.30 to $1.32 billion, representing growth of 32% to 34% compared to full year 2025. This compares to the prior range of $1.25 to

Benzinga Newsdesk

PRO
Guardant Health Q1 Adj. EPS $(0.45) Beats $(0.76) Estimate, Sales $301.665M Beat $279.198M Estimate

Guardant Health (NASDAQ:GH) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.76) by 40 percent. This is a 8.16 percent increase over losses of $(0.49) per share from the

Benzinga Newsdesk

PRO
Guardant Health Sees FY2026 Sales $1.250B-$1.280B vs $1.238B Est

Guardant Health (NASDAQ:GH) sees FY2026 sales of $1.250 billion-$1.280 billion vs $1.238 billion analyst estimate.

Benzinga Newsdesk

PRO
Guardant Health Q4 Adj. EPS $(0.50) Beats $(0.69) Estimate, Sales $281.266M Beat $271.011M Estimate

Guardant Health (NASDAQ:GH) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(0.69) by 28.06 percent. This is a 19.35 percent increase over losses of $(0.62) per share from the

Benzinga Newsdesk

Guardant Health Inc